NCT07000578

Brief Summary

Cerebral palsy (SP) is defined as a group of persistent disorders that cause activity limitation of movement and postural development. Children with cerebral palsy are typically born with a normal anatomical hip sequence. The incidence of hip dysplasia reported in patients with cerebral palsy ranges from 2% to 75%. Various non-surgical measures have been used to prevent or slow the progression of spastic hip dysplasia. The therapy program should include activities designed to sustain hip movement and promote weight bearing. However, there is no convincing evidence that treatment alone prevents hip subluxation. To prevent the progression of hip dysplasia, the physical therapy program should include activities designed to increase the functionality of the buttocks and promote weight bearing. In our study, standing strategies will be applied as conventional therapy. Orthotizing, corrective dynamic elastomeric fabric orthoses and taping applications are often used to prevent hip dysplasia. In our study, TheraTogs orthotic garment part, auxiliary dynamic belt material supporting muscles Tog-Rite will be used.Tog-Rite with a width of 7 cm will be made by applying approximately 50-60% stretch with spiral winding from the hip to the bottom of the knee. Positioning will be taught to families and instructed to wear 4 hours a day. Reminders will be made via remote weekly message, families will be able to reach the therapist at any time. Conventional therapy will continue for 2 sessions per week, 45 minutes in a clinical setting. T0: initial assessment, T1: 3ay conventional therapy, T3: 3 months of conventional therapy + positioning with spasticity, balance and impact on walking will be examined. Socia-demographic information forms of the children taken to the study will be recorded. According to the Gross Motor Function Classification System, children of the GMFCS I- II- III level will be taken to work. Children's independence levels will be determined and recorded with the Functional Independence Measure (WeeFIM). Muscle tone will be assessed by the Modified Ashworth Scale. The Pediatric Berg Balance Scale will be applied for functional balance. Balance measurement will be done with the Becure Balance System. Assessment of the gait will be done through the Gillette functional assessment questionnaire. The walking speed will be done with a 10 meter walking test.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
19

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jun 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 24, 2025

Completed
9 days until next milestone

Study Start

First participant enrolled

June 2, 2025

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 3, 2025

Completed
12 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 15, 2025

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 15, 2025

Completed
Last Updated

July 22, 2025

Status Verified

May 1, 2025

Enrollment Period

13 days

First QC Date

May 24, 2025

Last Update Submit

July 19, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Modified Ashworth Scale

    From enrollment to the end of treatment at treatment in 0, 3 months and 6 months

Eligibility Criteria

Age4 Years - 16 Years
Sexall
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Children with cerebral palsy

You may qualify if:

  • age range
  • Diagnosis of unilateral or bilateral spastic cerebral palsy
  • With a tendency to increase in hip muscle imbalance or hip adduction
  • At least 10 meters walkable (with independent or auxiliary device)
  • GMFCS I- II- III level according to the gross motor function classification system

You may not qualify if:

  • The presence of dysplasia of the hip
  • Severe adductor spasticity, Modified Ashworth Scale ≥ 3
  • Botulinum toxin injection into lower extremities in the last 6 months
  • Use of drugs to reduce spasticity
  • The presence of epilepsy
  • Mental inadequacy at a level that cannot understand commands

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

İstanbul Medipol University

Istanbul, Beykoz, 34810, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Cerebral Palsy

Condition Hierarchy (Ancestors)

Brain Damage, ChronicBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Officials

  • Devrim Tarakcı, Assoc. Dr.

    İstanbul Medipol University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 24, 2025

First Posted

June 3, 2025

Study Start

June 2, 2025

Primary Completion

June 15, 2025

Study Completion

December 15, 2025

Last Updated

July 22, 2025

Record last verified: 2025-05

Locations